Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leo Rasche

Showing results (101-110 of 170) with videos related to

Pageof 17
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|June 13, 2024
Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With TalquetamabAjai Chari, Amrita Krishnan, Leo Rasche, et al.
Blood|April 8, 2026
Phase 1/1b study of BCMA-targeting bispecific T-cell engager pavurutamab in relapsed/refractory multiple myelomaHans C Lee, Wouter J Plattel, Simon J Harrison, et al.
Nature Communications|November 28, 2019
On-target restoration of a split T cell-engaging antibody for precision immunotherapyAgnes Banaszek, Thomas G P Bumm, Boris Nowotny, et al.
Theranostics|August 15, 2022
Reduced splenic uptake on <sup>68</sup>Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosisSabrina Kraus, Philipp Klassen, Malte Kircher, et al.
Blood Advances|September 2, 2021
Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MMMarietta S Truger, Johannes Duell, Xiang Zhou, et al.
Haematologica|May 28, 2017
The level of deletion 17p and bi-allelic inactivation of <i>TP53</i> has a significant impact on clinical outcome in multiple myelomaSharmilan Thanendrarajan, Erming Tian, Pingping Qu, et al.
Blood|July 26, 2019
Hierarchy of mono- and biallelic <i>TP53</i> alterations in multiple myeloma cell fitnessUmair Munawar, Leo Rasche, Nicole Müller, et al.
Journal of Clinical Medicine|July 21, 2019
High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor MicroenvironmentAntonio Giovanni Solimando, Matteo Claudio Da Vià, Sebastiano Cicco, et al.
Haematologica|November 4, 2024
<i>Erratum</i> to: Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myelomaUmair Munawar, Johanna Theuersbacher, Maximilian J Steinhardt, et al.
Hemasphere|January 24, 2025
Combining SKY92 gene expression profiling and FISH (according to R2-ISS) defines ultra-high-risk Multiple MyelomaXiang Zhou, Annika Hofmann, Benedict Engel, et al.
Pageof 17

Showing results (101-110 of 170) with videos related to

Sort By:
Pageof 17
Clinical Lymphoma, Myeloma & Leukemia|June 13, 2024
Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With TalquetamabAjai Chari, Amrita Krishnan, Leo Rasche, et al.
Blood|April 8, 2026
Phase 1/1b study of BCMA-targeting bispecific T-cell engager pavurutamab in relapsed/refractory multiple myelomaHans C Lee, Wouter J Plattel, Simon J Harrison, et al.
Nature Communications|November 28, 2019
On-target restoration of a split T cell-engaging antibody for precision immunotherapyAgnes Banaszek, Thomas G P Bumm, Boris Nowotny, et al.
Theranostics|August 15, 2022
Reduced splenic uptake on <sup>68</sup>Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosisSabrina Kraus, Philipp Klassen, Malte Kircher, et al.
Blood Advances|September 2, 2021
Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MMMarietta S Truger, Johannes Duell, Xiang Zhou, et al.
Haematologica|May 28, 2017
The level of deletion 17p and bi-allelic inactivation of <i>TP53</i> has a significant impact on clinical outcome in multiple myelomaSharmilan Thanendrarajan, Erming Tian, Pingping Qu, et al.
Blood|July 26, 2019
Hierarchy of mono- and biallelic <i>TP53</i> alterations in multiple myeloma cell fitnessUmair Munawar, Leo Rasche, Nicole Müller, et al.
Journal of Clinical Medicine|July 21, 2019
High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor MicroenvironmentAntonio Giovanni Solimando, Matteo Claudio Da Vià, Sebastiano Cicco, et al.
Haematologica|November 4, 2024
<i>Erratum</i> to: Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myelomaUmair Munawar, Johanna Theuersbacher, Maximilian J Steinhardt, et al.
Hemasphere|January 24, 2025
Combining SKY92 gene expression profiling and FISH (according to R2-ISS) defines ultra-high-risk Multiple MyelomaXiang Zhou, Annika Hofmann, Benedict Engel, et al.
Pageof 17